Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights
Authors:
- 13 November 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (4) , 392-394
Abstract
Tebentafusp, recently approved by the FDA as an immunotherapy agent, has shown great promise in improving outcomes for metastatic uveal melanoma. In this case series, we present six patients treated with tebentafusp at our institution, focusing on the associated cutaneous adverse reactions and their management. A better understanding of the cutaneous adverse reactions associated with tebentafusp is important because, given its promising treatment outcomes, the use of tebentafusp will likely become more widespread. This study highlights the range of possible outcomes and effective treatment regimens for mild-to-severe cutaneous reactions, ensuring that patients can continue tebentafusp treatment without interruption in most cases.Keywords
This publication has 5 references indexed in Scilit:
- Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special ConsiderationsDrug Design, Development and Therapy, 2023
- Tebentafusp: a first-in-class treatment for metastatic uveal melanomaTherapeutic Advances in Medical Oncology, 2023
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialNature Medicine, 2022
- A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactionsAustralasian Journal of Dermatology, 2022
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaNew England Journal of Medicine, 2021